Back to Opportunities
Private Company  
Antibiotic-free microbial expression and genetic systems
What questions do you have about this RFP?
Get them answered by the team at the company.
Background

Biologics, including proteins, antibodies, and vaccines, are therapeutic products derived from living organisms and produced using microbial systems. In these systems, a host microorganism is engineered to carry a plasmid encoding the biologic of interest, along with an antimicrobial resistance (AMR) gene for selection purposes. The use of AMR genes allows only cells containing the plasmid to survive under antibiotic pressure, enabling large-scale production of the biologic. 

 

Regulatory agencies are currently discouraging the use of selection markers that could confer resistance to antibiotics to minimize theoretical risk of spreading antibiotic resistance traits to environmental microbial organisms. Agencies suggest that newly licensed biologics products should not contain any AMR genes. This includes removal of naturally occurring AMR genes from live bacteria through genetic modification. 

 

In response, a global fortune 500 company is seeking novel, cost-effective, antibiotic-free, endotoxin-free microbial expression systems for production of a wide range of biologics, including recombinant proteins, peptides, antigens, Fc-fusion proteins, and monoclonal antibodies. Additionally, the company seeks partners/technology to support removal of AMR genes through genetic modification.

What we're looking for

We are seeking microbial expression systems which do not contain AMR genes and/or technologies to engineer microbial cells to produce biologics without the use of antibiotics. The system should eventually support industrial-scale (1000L) bioreactors, ensure high protein yields, and maintain control over contamination and genetic stability during fermentation.

Solutions of interest include:
  • Use of essential gene(s) to select for expression plasmids which can be complemented by media additives during strain construction
  • Nutrient-dependent protein expression strains where only plasmid-carrying cells can survive in a nutrient-deficient medium (auxotrophic markers)
  • Plasmid addiction systems, such as metabolic burden-based and replication control systems
  • Other non-antibiotic selectable markers
  • Plasmid-free expression systems (e.g. genomic integration of target genes) which produce similar high yields as plasmid-based expression systems
  • Laboratories capable of gene editing/deletion in biosafety level 2 (BSL-2) pathogens
Our must-have requirements are:
  • Control of contamination and genetic drift
  • Avoid bovine/transmissible spongiform encephalopathies (BSE/TSE) risks and potential exposure to foreign animal diseases (FAD) of concern
  • Host strain and expression system free of AMR genes
  • High biologic yield
Our nice-to-have's are:
  • Cost-effective
  • Scalable manufacturing capability
  • Low or endotoxin-free host strains for protein expression
What's out of scope:
  • Plasmid selection relying on toxin/anti-toxin maintenance
  • CHO (Chinese hamster ovary) cells and other mammalian cell lines
Acceptable technology readiness levels (TRL):
Levels 3-9
What we can offer you
Eligible partnership models:
Sponsored research
Co-development
Licensing
Material transfer
Benefits:
Sponsored Research
Funding ranges from $50,000 to $200,000 over 1-2 years for further evaluation of potential leads, along with possible license of researcher's patented technologies.
Expertise
Partners will have access to industry experts in protein sciences, upstream and downstream processes, and manufacturing.
Q&A with the company

The Q&A is now closed.

Sort by:
Most upvoted
Q.
Is a yeast-based microbial expression system acceptable for this proposal?
1
A.
Hi Erin - Thanks for your question. We are most interested in bacterial expression systems, but if the yeast system is Pichia pastoris and does not require methanol for induction we will consider it. Thanks!
Team Member, Reviewer, Private Company
September 13, 2024
Is this response helpful?
0
0
A.
Thank you so much for the prompt response. With respect to the yeast species, we have built some platform S. cerevisiae strains that do not require methanol induction and that are cost-effective, antibiotic-free, and endotoxin-free. We have used these for the production of a wide range of biologics, including recombinant proteins, peptides, and antigens, at high levels. Would this platform be acceptable for this proposal?
1
A.
Hi Erin - Thanks for your response. Our team is interested in learning more about Renaissance Bioscience's platform. If you could submit a proposal / non-confidential overview, that'd be much appreciated. Thanks!
Team Member, Reviewer, Private Company
September 16, 2024
Is this response helpful?
1
0
A.
Absolutely! We appreciate your consideration of our platform. Thank you very much.
1
Q.
Could you clarify if you are looking for an existing expression/production system to license or if you have existing strains and are looking for partners to engineer those strains
1
A.
For protein expression we prefer a bacterial system that can be licensed for commercial use (after in-house testing). However, on occasion we have bacterial strains for expression or other purposes where we need to remove naturally occurring genes from the chromosome (eg. engineering).
Team Member, Reviewer, Private Company
September 19, 2024
Is this response helpful?
0
0
Share Opportunity
Complete
Seeking partners focused on
Analytical Chemistry
Antimicrobials
Artificial Intelligence
Biochemistry
Biocides
Bioinformatics
Biological Complexity
Biomolecular Processes
Biopharmaceutics
Biophysics
51 more
Biosensors
Biosystems
Cell Assembly
Cell Biology
Cell Membrane Transport
Complex Systems
Computational Biology
Genetics
Genomics
Growth Processes
Industrial Chemistry
Infectious Diseases
Intracellular Signalling
Intracellular Trafficking
Intracellular Transport
Medicinal Chemistry
Membranes
Metabolomics
Microbiology
Microbiome
Microfluidics
Molecular Biology
Molecular Medicine
Nanoengineering
Nanotechnology
Organic Chemistry
Pharmaceutical Chemistry
Pharmacogenetics
Pharmacology
Physical Chemistry
Physiology
Protein Structure Prediction
Proteomics
Regenerative Medicine
Structural Biology
Sustainability
Synthetic Biology
Systems Biology
Theoretical Biology
Thermodynamics
Toxicology
Translational Science
Virology
Biotechnology
Biology
Biomedical Engineering
Chemical Engineering
Chemistry
Computer Science
Industrial Engineering
Materials Science
Halo home
Discover tomorrow's
breakthroughs today.
Get new partnering opportunities
delivered to your inbox.
© 2023 Halo Cures, Inc.